Pneumococcal vaccine - Aventis PasteurAlternative Names: Pneumococcal surface protein A DNA vaccine - Aventis Pasteur; Pneumococcal surface protein A vaccine - Aventis Pasteur
Latest Information Update: 27 Nov 2002
At a glance
- Originator Nonindustrial source; sanofi pasteur
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Pneumococcal infections